A. Banerjee

First name
A.
Last name
Banerjee
Archer, L., Koshiaris, C., Lay-Flurrie, S., Snell, K. I. E., Riley, R. D., Stevens, R., et al. (2022). Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study. Bmj, 379, e070918. http://doi.org/10.1136/bmj-2022-070918
View
Mizani, M. A., Dashtban, A., Pasea, L., Lai, A. G., Thygesen, J., Tomlinson, C., et al. (2022). Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med, 1410768221131897. http://doi.org/10.1177/01410768221131897
View
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
View
Birkeland, K. I., Bodegard, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., et al. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189
View
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
View
Dashtban, A., Mizani, M. A., Denaxas, S., Nitsch, D., Quint, J., Corbett, R., et al. (2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. http://doi.org/10.1016/j.kint.2022.05.015
View
Denaxas, S., Gonzalez-Izquierdo, A., Direk, K., Fitzpatrick, N. K., Fatemifar, G., Banerjee, A., et al. (2019). UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. J Am Med Inform Assoc. http://doi.org/10.1093/jamia/ocz105
View
Banerjee, A., Allan, V., Denaxas, S., Shah, A., Kotecha, D., Lambiase, P. D., et al. (2019). Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. Europace. http://doi.org/10.1093/europace/euz220
View
Uijl, A., Koudstaal, S., Direk, K., Denaxas, S., Groenwold, R. H. H., Banerjee, A., et al. (2019). Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records. Eur J Heart Fail. http://doi.org/10.1002/ejhf.1350
View
Katsoulis, M., Pasea, L., Lai, A. G., Dobson, R. J. B., Denaxas, S., Hemingway, H., & Banerjee, A. (2020). Obesity during the COVID-19 pandemic: both cause of high risk and potential effect of lockdown? A population-based electronic health record study. Public Health. http://doi.org/10.1016/j.puhe.2020.12.003
View